Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• , Pfizer-BioNTech COVID-19 in 2021 [99] and Moderna COVID-19 Vaccine in 2022 [100], after the approval in 2018 of Onpattro (Patisiran) [101], the first gene therapy based on lipid nanoparticles containing RNA interference, for the treatment of hereditary transthyretin-mediated amyloidosis. Vaccines made of

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• the limitations of the conjugates [68][69]. Cytotoxic or molecular targeting agents with siRNA Targeting homologous mRNA sequences in cells and knockdown of receptors involved in cell survival and proliferation using RNA interference downregulates receptor protein expression, inhibits cell growth, and

• contribute to cancer therapy resistance encouraged the therapeutic application of RNA interference as a powerful tool to fight resistant tumors. Knockdown of oncogenic genes involved in drug resistance combined with traditional therapy or molecularly targeted agents for subsequent tumor killing may alleviate

Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes

• Alfredo Nuñez-Rivera,
• Pierrick G. J. Fournier,
• Danna L. Arellano,
• Ana G. Rodriguez-Hernandez,
• Rafael Vazquez-Duhalt and
• Ruben D. Cadena-Nava

Beilstein J. Nanotechnol. 2020, 11, 372–382, doi:10.3762/bjnano.11.28

• therapies, this virus could act as an immunoregulator in immunological therapies to improve some cancer treatments [47][48]. VLP-siRNA synthesis and characterization Gene silencing through RNA interference (RNAi) is considered to be among the most promising therapies to fight cancer. RNAi pathway influences

Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine

• Valentina Francia,
• Daphne Montizaan and
• Anna Salvati

Beilstein J. Nanotechnol. 2020, 11, 338–353, doi:10.3762/bjnano.11.25

• endocytosis and caveolae-mediated endocytosis. Hence, perturbing the activity of actin affects multiple pathways at the same time [212]. Several techniques can be used for studying the endocytic mechanisms of nano-sized materials, each one with its advantages and drawbacks [22][133]. Among those, RNA

• interference (RNAi) is often used to shut down the expression of a single protein or even a single isoform. However, the complete depletion of the protein of interest after RNAi requires at least 48–96 h and during this time cells can adapt, for example by upregulating other proteins of the same family or

Internalization mechanisms of cell-penetrating peptides

• Ivana Ruseska and
• Andreas Zimmer

Beilstein J. Nanotechnol. 2020, 11, 101–123, doi:10.3762/bjnano.11.10

• -mediated endocytosis. RNA interference-mediated knockdown experiments in combination with pharmacological inhibitors support their results. These results contradict the former findings of the group, which stated that syndecans were involved in the uptake of R8 via macropinocytosis. However, there is a

Frontiers in pharmaceutical nanotechnology

• Matthias G. Wacker

Beilstein J. Nanotechnol. 2019, 10, 2538–2540, doi:10.3762/bjnano.10.244

• announced the approval of a first-of-its-kind RNA interference (RNAi)-based drug, Onpattro™, which uses solid lipid nanoparticles to protect the sensitive compound from early degradation. Again, lipid materials rather than synthetic polymers have been used for drug delivery applications. In pharmaceutical

Enhanced antineoplastic/therapeutic efficacy using 5-fluorouracil-loaded calcium phosphate nanoparticles

• Shanid Mohiyuddin,
• Saba Naqvi and
• Gopinath Packirisamy

Beilstein J. Nanotechnol. 2018, 9, 2499–2515, doi:10.3762/bjnano.9.233

Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl–dextran–MMA graft copolymer and paclitaxel used as an artificial enzyme

• Yasuhiko Onishi,
• Yuki Eshita,
• Rui-Cheng Ji,
• Masayasu Onishi,
• Takashi Kobayashi,
• Masaaki Mizuno,
• Jun Yoshida and
• Naoji Kubota

Beilstein J. Nanotechnol. 2014, 5, 2293–2307, doi:10.3762/bjnano.5.238

• levels and the decrease of eNOS in individual mice was checked using phoresis and the RT-PCR findings of the mouse in the DDMC/PTX group. The down-regulation of eNOS (an angiogenesis regulator) protein should be predominantly carried out by using RNA interference induced by miR-222 following “Argonaute

Molecular biology approaches in bioadhesion research

• Marcelo Rodrigues,
• Birgit Lengerer,
• Thomas Ostermann and
• Peter Ladurner

Beilstein J. Nanotechnol. 2014, 5, 983–993, doi:10.3762/bjnano.5.112

• hybridization screen, and (4) functional analyses of selected genes by using RNA interference knock-down. Furthermore, latest developments in genome-editing are presented as new tools to study gene function. By using this iterative multi-technologies approach, the identification, isolation, expression and

• expression; in situ hybridization; RNA interference; transcriptome; Introduction The capability of an organism to attach to a surface, either temporarily or permanently, is referred to as “bioadhesion”. Bioadhesion occurs in many living organisms that have designed ways to adhere to a range of surfaces [1

• assembled hypothetical complementary DNA originating from isolated messenger RNA) expressed in the region of the animal containing adhesive-producing cells; secondly, in situ hybridization (ISH) screening provides the (temporal and) spatial expression of target transcripts; thirdly, RNA interference (RNAi